Fritextsökning
Innehållstyper
-
First injectable cancer medicine for home use receives green light
Johnson & Johnson has announced that its blockbuster cancer medicine Darzalex (daratumumab) is set to become the first injectable cancer treatment in Europe sui...
-
Computed tomography in measurement of medical plastic products
Watch the recordings from ZEISS Quality Innovation Summit.
-
How MoniDose strengthened their regulatory confidence—fast
When MoniDose began their startup journey, regulations were their biggest challenge. Missing early design inputs tied to standards could have meant costly redesigns later.
-
From Image to Results
3D multiplexing spatial omics workflows in neuroscience.
-
A new scientific event in Gothenburg
Life Science Sweden is holding an event in Gothenburg for the first time.
-
Clinical trials: proposals, budgets, and the evolving CRO role
This podcast episode from Trustful Clinical Budgeting dives into what really makes proposals work in clinical trials and why clarity, early alignment, and reali...
-
National cord blood bank resumes collection
The collection of umbilical cord blood is now resuming during planned caesarean sections at Östra Hospital in Gothenburg. The blood remaining in the placenta an...
-
Pharmafond tredubblar sitt kapital inför nya investeringar
Investeringsbolaget Jeito Capital har tagit in 1,2 miljarder dollar i vad bolaget beskriver som ”den största kapitalresningen någonsin” för en oberoende europei...
-
Lif:s vd får tung post i MVA
Lif:s vd Sofia Wallström har valts in till styrelsen och posten som ny vice ordförande i Medicon Valley Alliance, MVA. Samtidigt stärks den nordiska representat...
-
Long-Term Volumetric Imaging of Living Cells
ZEISS Lattice Lightsheet 7.
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
End of bone‑sawing? New laser cuts to record depths
Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have disc...
-
Regionerna ändrar riktning – öppnar för fler trepartsöverläggningar
Efter en mer restriktiv linje sänker regionerna nu tröskeln för trepartsöverläggningar med TLV och läkemedelsbolag – en förändring som potentiellt kan ge fler l...
-
Drug approved for condition causing extreme hunger
The U.S. Food and Drug Administration (FDA) has for the first time approved a drug for acquired hypothalamic obesity, a condition marked by rapid weight gain dr...
-
Supporting Investigator Initiated Clinical Studies—From Start to Finish
Many important clinical studies start with researchers – not pharmaceutical companies. In investigator initiated studies, pharmaceutical companies often support...
-
A food-based strategy to stop gut infections early
Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier b...
-
Trump in new push to lower drug prices
U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...
-
New global standard for clinical evaluation is on the horizon: ISO/DIS 18969
A new global standard for clinical evaluation is on the horizon: ISO/DIS 18969. The core message is straightforward: clinical evaluations should be seen as a pr...
-
Conjugate Planes in Microscopy
Knowledge Article from ZEISS.
-
Xbrane tar in 240 miljoner – satsar vidare på biosimilarprojekt
Biosimilarutvecklaren Xbrane Biopharma tar in 240 miljoner kronor i en riktad nyemission, som var övertecknad.
-
Any Image Size, Many Formats, AI-Powered
ZEISS arivis optimizes local server or cloud computation resources.
-
Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”
Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilie...
-
Pila Pharma tar in 20 miljoner kronor – inleder ”dedikerat fetmaspår”
Malmöbolaget Pila Pharma utvecklar ett nytt, oralt läkemedel för behandling av typ 2-diabetes. Ett nytt kapitaltillskott ska användas för att initiera studier o...
-
Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”
The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a r...
BREAKING